RJT
BMY.RT

Raymond James Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Raymond James Trust’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-23,433
Closed -$53K – 1161
2020
Q4 		$53K Sell
23,433
-5,869
-20% -$12.5K ﹤0.01% 1033
2020
Q3 		$66K Sell
29,302
-78
-0.3% -$223 ﹤0.01% 959
2020
Q2 		$66K Buy
29,380
+4,920
+20% +$17.8K ﹤0.01% 913
2020
Q1 		$55K Sell
24,460
-547
-2% -$1.8K ﹤0.01% 804
2019
Q4 		$56K Buy
+25,007
New +$65K ﹤0.01% 955

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Raymond James Trust's BMY.RT Position: Q1 2021 in Review

Raymond James Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 23,433 shares — an estimated $53K sold.

Raymond James Trust first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $66K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Raymond James Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Raymond James Trust sold 23,433 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $53K.
  • Raymond James Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Raymond James Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $66K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Raymond James Trust's 13F filing for Q1 2021, filed 3 May 2021.